Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis.
Russo V, Fabiani D, Leonardi S, Attena E, D'Alterio G, Cotticelli C, Rago A, Sarpa S, Maione B, D'Onofrio A, Golino P, Nigro G.
Russo V, et al. Among authors: maione b.
J Cardiovasc Pharmacol. 2023 Feb 1;81(2):129-133. doi: 10.1097/FJC.0000000000001382.
J Cardiovasc Pharmacol. 2023.
PMID: 36607629